Myeloid-derived Suppressor Cells in Human Cancer

Overview

Journal Cancer J

Specialty Oncology

Date 2010 Aug 10

PMID 20693846

Citations 138

Authors

Srinivas Nagaraj

Dmitry I Gabrilovich

Affiliations

Soon will be listed here.

Abstract

Myeloid-derived suppressor cells are one of the major factors responsible for immune suppression in cancer. They also contribute to limited efficacy of current vaccination strategies. Here, we give an overview of the myeloid-derived suppressor cells field focusing primarily on the studies in cancer patients and current and future therapeutic options targeting these cells.

Citing Articles

Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).

Mousa A, Enk A, Hassel J, Reschke R Cells. 2024; 13(19.

PMID: 39404378 PMC: 11475876. DOI: 10.3390/cells13191615.

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.

Ozbay Kurt F, Lasser S, Arkhypov I, Utikal J, Umansky V J Clin Invest. 2023; 133(13).

PMID: 37395271 PMC: 10313369. DOI: 10.1172/JCI170762.

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients.

Mirjacic Martinovic K, Vuletic A, Tisma Miletic N, Nedeljkovic M, Babovic N, Matkovic S Innate Immun. 2023; 29(3-4):37-44.

PMID: 37160888 PMC: 10331212. DOI: 10.1177/17534259231172079.

Understanding the squamous cell carcinoma immune microenvironment.

Saeidi V, Doudican N, Carucci J Front Immunol. 2023; 14:1084873.

PMID: 36793738 PMC: 9922717. DOI: 10.3389/fimmu.2023.1084873.

Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors.

Ji X, Jiang W, Wang J, Zhou B, Ding W, Liu S Front Immunol. 2023; 13:1106644.

PMID: 36713375 PMC: 9877461. DOI: 10.3389/fimmu.2022.1106644.